MSD Biotech wins CURT Project Excellence category award

Now at completion, the 30,000 sq.m. development will play a pivotal role in the manufacture of MSD’s biologics-based medicines, including in the area of immuno-oncology. It will also expand MSD’s current internal network of biologics drug substance manufacturing plants. Full manufacturing operations are expected to commence in 2021.

The €750m project, for which EPCMCQ was managed by a JV of PM Group and Jacobs Engineering, has set a new benchmark with respect to excellence in project delivery for biopharmaceutical facilities. During construction, in excess of 4.8 million hours were worked onsite without a Lost Time Incident (LTI). This achievement required conscious, continuous focus on planning, coordination and cooperation of all stakeholders.

“This impressive facility is a testament to the collaboration and exceptional effort of all those who worked on the project” said John Hassett, Project Construction Director.

More about this project

Congratulations also to the MSD GES (Global Engineering Services) Team who have won a CURT Safety Excellence Award.  

As an MSD EPCM partner, PM Group continues to deliver projects in Ireland, Western Europe, China and Singapore as well as managing three OEP sites in Ireland at Ballydine, Brinny and Carlow.